An open-label, multi-center phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma.
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Amgen
- 12 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Jul 2010 Planned end date changed from 1 Dec 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.